JP Morgan Chase
OREX

JP Morgan Chase’s Orexigen Therapeutics, Inc. OREX Stock Holding History

JP Morgan Chase’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-10,000
Closed -$211K – 4992
2015
Q3 		$211K Buy
+10,000
New +$343K ﹤0.01% 3670
2014
Q4 		– Sell
-10,000
Closed -$426K – 4577
2014
Q3 		$426K Buy
+10,000
New +$537K ﹤0.01% 3730

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
GL
GLG LLC New York $1.39B AUM 24.01% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

JP Morgan Chase's OREX Position: Q4 2017 in Review

JP Morgan Chase sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2017, closing a stake of 500 shares — an estimated $1K sold.

JP Morgan Chase first reported a position in OREX in Q2 2013 and held it in 18 quarters. The position peaked at $5.18M in Q4 2014. 41 funds tracked by Wall St. Rank hold OREX as of Q4 2017.

  • JP Morgan Chase reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • JP Morgan Chase sold 500 Orexigen Therapeutics, Inc. shares in Q4 2017, an estimated $1K.
  • JP Morgan Chase first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 18 quarters.
  • JP Morgan Chase's Orexigen Therapeutics, Inc. position peaked at $5.18M in Q4 2014.
  • 41 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2017.

Based on JP Morgan Chase's 13F filing for Q4 2017, filed 13 Feb 2018.